Hyun Joo Lee

Dr. Hyun Joo Lee

Gastroenterology, Samsung Medical Center, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Cancer Letters
Verified
Journal Article
Closed access
HLHyun Joo Lee
Hyun Joo Lee
WDWoo Kyung Lee Doolittle
Woo Kyung Lee Doolittle
CKChan Woo Kang
Chan Woo Kang
Cheol Ryong KuCheol Ryong Ku
Cheol Ryong Ku
YCYoon Hee Cho
Yoon Hee Cho
ELEunjig Lee
Eunjig Lee

12 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HLHyun Joo Lee
Hyun Joo Lee
Background: Although intestinal fibrosis is a consequence of recurrent inflammation in Inflammatory bowel disease (IBD), alleviating inflammation alone does not prevent the progression of fibrosis, suggesting that the development of direct anti-fibrotic agents is necessary. This study aimed to evaluate the anti-fibrotic properties of combination treatment with pentoxifylline (PTX) and vitamin E (Vit-E) on human primary intestinal myofibroblasts (HIMFs) and the therapeutic potential of the combination therapy in murine models of IBD. Methods: HIMFs were pretreated with PTX, Vit-E, or both, and incubated with TGF-β1. We performed Western blot, qPCR, collagen staining, and immunofluorescence to estimate the anti-fibrotic effects of PTX and Vit-E. The cytotoxicity of these was investigated through MTT assay. To induce murine models of IBD for in vivo study, C57BL/6 mice were treated with repeated cycles of dextran sulfate sodium (DSS), developing chronic colitis. We examined whether the combined PTX and Vit-E treatment would effectively ameliorate colonic fibrosis in vivo. Results: We found that the co-treatment with PTX and Vit-E suppressed TGF-β1-induced expression of fibrogenic markers, with decreased expression of pERK, pSmad2, and pJNK, more than either treatment alone in HIMFs. Neither PTX nor Vit-E showed any significant cytotoxicity in given concentrations. Consistently with the in vitro results, the co-administration with PTX and Vit-E effectively attenuated colonic fibrosis with recovery from thickening and shortening of colon in murine models of IBD. Conclusions: These findings demonstrated that the combination of PTX and Vit-E exhibits significant anti-fibrotic effects in both HIMFs and in vivo IBD models, providing a promising therapy for IBD.

1 February 2023 in Journal of Autoimmunity
Verified
Journal Article
Closed access
HLHyun Joo Lee
Hyun Joo Lee
SLSeung Won Lee
Seung Won Lee
HCHye Ryeong Cha
Hye Ryeong Cha
EHEun Kyo Ha
Eun Kyo Ha
JKJu Hee Kim
Ju Hee Kim
MGM. Eric Gershwin
M. Eric Gershwin

26 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
HLHyun Joo Lee
Hyun Joo Lee
MCMoon Seok Choi
Moon Seok Choi
BSByeong Geun Song
Byeong Geun Song
WKWonseok Kang
Wonseok Kang
GGGeum Youn Gwak
Geum Youn Gwak
DSDong Hyun Sinn
Dong Hyun Sinn
Early-stage hepatocellular carcinoma (HCC) is still difficult to cure for its high recurrence rate. This study aimed to examine whether glycemic burden management could be one way to improve outcomes of early-stage HCC. A total of 137 very early or early-stage HCC patients who underwent resection or ablation at Samsung Medical Center and had glycemic burden assessment were analyzed. Glycemic burden was assessed using hemoglobin A1c (HbA1c) level. Outcomes were recurrence and overall survival. Risks of recurrence and overall survival were compared according to glycemic burden using a cut-off point of 6.5% or two cut-off points of 6.0% and 7.5%. Overall, 51 (37.2%) patients experienced HCC recurrence. The adjusted hazard ratio (aHR) for recurrence comparing patients with HbA1c > 6.5% to those with HbA1c ≤ 6.5% was 2.66 (95% CI: 1.26–5.78). The risk of recurrence increased in a dose-dependent manner by glycemic burden; aHR for 6.0 < HbA1c ≤ 7.5%: 2.00 (95% CI: 0.78–5.55); aHR for HbA1c > 7.5%: 6.05 (95% CI: 2.31–17.5). Mortality was observed in 16 (11.7%) patients. The risk of mortality was higher for HbA1c > 6.5% than for HbA1c ≤ 6.5% (aHR: 2.33; 95% CI: 1.10–5.08). There was also a dose–response relationship between overall survival and glycemic burden. Glycemic burden assessed using HbA1c level was significantly associated with outcomes of early-stage HCC patients. Good glycemic control could be a therapeutic goal to improve clinical outcomes in these populations.